BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.18.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20260101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270224
DTSTAMP:20261106T112904Z
CREATED:20261106T112904Z
LAST-MODIFIED:20261106T112904Z
UID:44719-1803254400-1803427199@www.pharmajournalist.com
SUMMARY:SmartLab Exchange Europe 2027
DESCRIPTION:SmartLab Exchange Europe 2027 is the invitation-only forum for senior laboratory\, digital transformation\, data and R&D leaders responsible for accelerating innovation and driving digital transformation across the life sciences and process industries. Bringing together decision-makers from pharmaceutical\, biotech\, FMCG\, food & beverage and chemicals organisations\, the event provides a unique platform to explore the technologies\, strategies and operating models shaping the future of scientific research and development. \nAs organisations seek to operationalise artificial intelligence and advanced digital technologies\, many continue to face challenges including fragmented data environments\, disconnected laboratory systems\, workforce adoption barriers and difficulties scaling AI beyond proof-of-concept projects. SmartLab Exchange Europe 2027 addresses these challenges by focusing on practical\, real-world approaches to achieving successful R&D transformation and delivering measurable business value from digital initiatives. \nThe 2027 programme explores key industry priorities including AI-ready data foundations\, trusted AI governance\, laboratory orchestration\, connected scientific ecosystems\, workforce transformation and the emergence of self-driving laboratories. Through a combination of peer-led case studies\, panel discussions\, think tanks\, interactive roundtables and one-to-one meetings\, attendees will gain actionable insights from organisations successfully implementing AI\, automation and digital innovation across laboratory and R&D environments. \nAttendees will have the opportunity to benchmark their strategies against industry peers\, discover how leading organisations are building scalable AI capabilities\, and explore approaches to improving data quality\, interoperability and digital adoption across the laboratory landscape. The event also examines how organisations can create trusted foundations for AI\, connect previously siloed systems and transform laboratory operations to support faster\, more informed scientific decision-making. \nThe event features senior leaders from organisations including AstraZeneca\, Novartis\, Johnson & Johnson\, Kenvue and Henkel\, alongside an extensive faculty of laboratory\, digital and R&D transformation experts. Designed for leaders shaping the future of laboratory operations and scientific innovation\, SmartLab Exchange Europe 2027 offers a valuable opportunity to exchange best practices\, explore emerging technologies and build the partnerships needed to accelerate product development and unlock the full potential of AI-powered R&D. \nTo know more visit: https://bit.ly/4BHlPdJ
URL:http://www.pharmajournalist.com/event/smartlab-exchange-europe-2027/
LOCATION:Leonardo Royal Hotel Amsterdam\, Paul van Vlissingenstraat 24\, Amsterdam\, 1096 BK\, Netherlands
ORGANIZER;CN="IQPC Exchange":MAILTO:enquire@iqpcexchange.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270226
DTSTAMP:20261028T115729Z
CREATED:20261028T115729Z
LAST-MODIFIED:20261028T115729Z
UID:44627-1803340800-1803599999@www.pharmajournalist.com
SUMMARY:3rd Annual TRP Target Selection & Drug Design Summit
DESCRIPTION:The 3rd Annual TRP Target Selection & Drug Design Summit is the industry-dedicated discovery and preclinical forum for advancing the next generation of targeted radiopharmaceutical therapies. Taking place in Boston from February 23-25\, 2027\, the summit will unite more than 100 experts from across discovery\, biology\, medicinal chemistry\, radiochemistry\, ADME/DMPK\, toxicology\, radiobiology\, dosimetry\, preclinical development\, translational science\, and business development. \nAs established targets such as PSMA become increasingly crowded\, the meeting will help radiopharmaceutical developers identify novel targets\, explore new disease settings\, and create differentiated candidates with stronger clinical potential. Attendees will examine how clinically validated targets from ADCs\, RDCs\, immuno-oncology\, and other targeted modalities can be assessed and translated into radioligand therapy programs. \nThe agenda will explore emerging targets across CAIX\, MSLN\, the brain\, extracellular matrix\, and leukocytes\, alongside the biological factors that determine suitability for radiopharmaceutical development. Discussions will also cover targeting moieties\, linkers\, chelators\, radionuclide selection\, biodistribution\, kinetic imaging\, total-body PET\, digital SPECT\, computational biology\, dosimetry\, organ-specific toxicity\, and preclinical safety strategy. \nTwo interactive pre-conference workshops will provide focused learning on using advanced imaging and computational biology to identify high-potential targets\, as well as mining clinical validation from other therapeutic modalities to accelerate target selection. Across the main conference\, presentations\, roundtables\, case studies\, and networking sessions will help attendees benchmark candidate design and determine the evidence required to advance programs confidently toward the clinic. \nWith contributions from experts representing Bayer\, AstraZeneca\, Molecular Partners\, Mariana Oncology\, Harvard Medical School\, United Theranostics\, Ratio Therapeutics\, Affibody\, and other leading organizations\, the summit offers a focused opportunity to improve target selection\, strengthen drug design\, and build safer\, more differentiated radiopharmaceutical pipelines. \nTo know more visit: https://ter.li/ugtcnsbo
URL:http://www.pharmajournalist.com/event/3rd-annual-trp-target-selection-drug-design-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270224
DTEND;VALUE=DATE:20270226
DTSTAMP:20261110T132343Z
CREATED:20261110T132343Z
LAST-MODIFIED:20261110T132343Z
UID:44746-1803427200-1803599999@www.pharmajournalist.com
SUMMARY:5th Viral Vector Process Development & Manufacturing Summit
DESCRIPTION:The 5th Annual Viral Vector Process Development & Manufacturing Summit brings together leaders across CMC\, process development\, manufacturing\, MSAT\, operations\, and regulatory affairs to advance robust\, reliable\, and reproducible viral vector manufacturing platforms. As the industry shifts towards optimizing proven AAV and LVV platforms\, the summit focuses on overcoming the challenges of scalable manufacturing\, process consistency\, regulatory readiness\, and commercial success. \nThrough real-world case studies\, scientific presentations\, panel discussions\, and networking opportunities\, attendees will explore strategies to improve vector yield\, enhance empty/full capsid separation\, optimize transfection and purification processes\, reduce cost of goods\, and accelerate development timelines through platform-based manufacturing approaches. \nThe summit will showcase practical insights from leading biopharma and biotech organizations including Regeneron\, Sanofi\, Ultragenyx\, Legend Biotech\, Cabaletta Bio\, and Apertura Gene Therapy\, providing attendees with actionable strategies to strengthen manufacturing performance\, improve product quality\, and support successful clinical and commercial outcomes. \nJoin a community of viral vector experts dedicated to increasing productivity\, reducing manufacturing and CMC burden\, and building the scalable processes needed to deliver the next generation of cell and gene therapies. \nFind out more today and secure your complimentary ticket: https://ter.li/2pthcqqz
URL:http://www.pharmajournalist.com/event/5th-viral-vector-process-development-manufacturing-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270312
DTSTAMP:20261103T120728Z
CREATED:20260925T071331Z
LAST-MODIFIED:20261103T120728Z
UID:44434-1804464000-1804809599@www.pharmajournalist.com
SUMMARY:17th World ADC London
DESCRIPTION:17th World ADC London | 8-11th March 2027 | London\, UK\nThe 17th World ADC London will bring together the global ADC community to explore the science\, strategic insights and partnerships shaping the future of antibody-drug conjugate (ADC) development. Taking place from 8-11th March 2027 in London\, the event will bring together more than 700 leaders from biopharma\, biotech\, academia\, investment and solution provider organisations for Europe’s largest annual gathering dedicated to the ADC community. \nAs ADCs continue to gain momentum across oncology\, the industry faces a new generation of challenges and opportunities. From overcoming resistance mechanisms and improving patient response rates to advancing differentiated designs and scaling manufacturing\, the need for collaboration and knowledge-sharing has never been greater. World ADC London provides a platform for the community to exchange ideas\, learn from emerging data and explore the strategies driving the next wave of innovation. \nThe programme spans the full ADC development journey\, covering discovery\, preclinical and translational development\, clinical development\, process and analytical development\, and manufacturing. Attendees will hear from 110 speakers from across Europe\, North America and Asia\, sharing data-driven insights\, case studies and practical approaches across ADC development. \nWith a strong focus on next-generation ADC innovation and differentiation\, the programme will explore approaches including novel cytotoxic and non-cytotoxic payloads\, dual-payload ADCs and bispecific ADCs\, alongside strategies to move beyond established payloads and targets and advance the next generation of ADCs. \nMore than just a scientific meeting\, World ADC London is recognised as an annual meeting point for the global ADC community. For 17 years\, it has brought together established leaders\, emerging biotech companies\, investors and technology innovators in an environment designed to foster meaningful connections and productive discussions. Whether you are looking to benchmark your strategy\, identify new partners\, discover enabling technologies or gain a broader understanding of the competitive landscape\, the event offers opportunities to connect with the people shaping the field. \nWith extensive networking opportunities\, dedicated partnering experiences and cutting-edge scientific content\, World ADC London remains a key forum for those involved in ADC development. Explore the programme to discover the discussions\, emerging data and connections shaping the next chapter of ADC innovation. \nView the agenda here:  https://ter.li/orip0z61
URL:http://www.pharmajournalist.com/event/17th-world-adc-london/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270317
DTEND;VALUE=DATE:20270320
DTSTAMP:20261029T123304Z
CREATED:20261029T123304Z
LAST-MODIFIED:20261029T123304Z
UID:44642-1805241600-1805500799@www.pharmajournalist.com
SUMMARY:11th Liquid Biopsy for Precision Oncology Summit West Coast
DESCRIPTION:The way precision medicine teams design and execute clinical trials today is reshaping the fundamentals of drug development. Teams that have not yet integrated novel liquid biopsy technologies into their programs are already falling behind their peers. \nThe 11th Liquid Biopsy for Precision Oncology Summit West Coast provides a much-needed space to spotlight how pharma are driving liquid biopsy adoption\, whilst addressing the challenges of implementing this powerful new tool across the clinical development lifecycle. \nUniting 250+ biopharma\, diagnostic\, consortia\, academic and patient voices\, this globally renowned meeting continues to house the discussions and collaborations informing the future of the liquid biopsy community. \nSessions will cover dose optimization through to therapeutic monitoring\, patient selection\, multi-omics and beyond\, to ensure your entire team walks away with insights they can apply to their day-to-day role. \nIf you are looking to build the connections and unlock the best-in-class solutions for liquid biopsy application\, this is the room you need to be in. \nWith free* passes available to eligible biopharma and researchers\, don’t pass up the opportunity to join us and the complete West Coast precision medicine community next March. \nTo know more visit: https://ter.li/iod244e2
URL:http://www.pharmajournalist.com/event/11th-liquid-biopsy-for-precision-oncology-summit-west-coast/
LOCATION:Hyatt Regency Mission Bay\, 1441 Quivira Road\, San Diego\, CA\, 92109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270326
DTSTAMP:20261112T123227Z
CREATED:20261112T123227Z
LAST-MODIFIED:20261112T123227Z
UID:44751-1805760000-1806019199@www.pharmajournalist.com
SUMMARY:7th Operationalize: Expanded Access Programs Summit
DESCRIPTION:The 7th Operationalize: Expanded Access Programs Summit returns at a pivotal moment as Expanded Access Programs evolve beyond a purely operational function to become a strategic component of patient access\, evidence generation\, post-trial planning\, and commercial readiness. As organizations expand access into new global markets and face growing expectations around real-world data\, patient continuity\, and reimbursement transitions\, EAP leaders are under increasing pressure to build scalable\, sustainable\, and patient-centric programs. \nAs the industry’s leading forum dedicated to Expanded Access\, this meeting brings together pharma\, biotech\, patient advocacy\, and access leaders to address the most pressing challenges shaping the future of global patient access\, including: \n\nStrengthening global post-trial access strategies to ensure long-term patient continuity while navigating regional regulatory and reimbursement complexities\nLeveraging real-world data generated through Expanded Access to support clinical development\, regulatory strategy\, and future market access decisions\nNavigating complex global access pathways across established and emerging markets while adapting programs to diverse healthcare systems and local requirements\nBuilding sustainable and scalable EAP models through improved governance\, regulatory intelligence\, operational frameworks\, and digital innovation\n\nWhat to Expect: \n\n150+ Pharma\, Biotech & Patient Access Leaders\n20+ Expert Speakers from Takeda\, Regeneron\, Alexion\, Alnylam\, Merck\, Sanofi & More\nInteractive Regional Networking & Peer Benchmarking Sessions\nDedicated Workshops Covering EAP Strategy\, Operations & Post-Trial Access\nLive Problem-Solving Discussions & Access Insights Poster Exchanges\n\nBringing together leaders responsible for medical affairs\, patient access\, clinical operations\, regulatory strategy\, and late-phase development\, this industry-led summit offers a unique opportunity to benchmark approaches\, share practical lessons\, and build meaningful connections with peers navigating the same challenges. \nBy attending\, you’ll be in the room with professionals from Takeda\, Regeneron\, Alexion\, Alnylam\, Merck\, Sanofi\, Sarepta Therapeutics\, Jazz Pharmaceuticals\, Beam Therapeutics\, Amylyx and more. \nAcross three days of workshops\, case studies\, panel discussions\, and networking\, gain practical insights into global access strategy\, post-trial access\, real-world data generation\, reimbursement transitions\, and regulatory intelligence while helping shape the future of Expanded Access Programs. \nDiscover the Full 2027 Agenda Here: https://ter.li/5w26qieq
URL:http://www.pharmajournalist.com/event/7th-operationalize-expanded-access-programs-summit/
LOCATION:Hilton Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270326
DTSTAMP:20261112T125518Z
CREATED:20261112T125300Z
LAST-MODIFIED:20261112T125518Z
UID:44759-1805760000-1806019199@www.pharmajournalist.com
SUMMARY:10th Antigen-Specific Immune Tolerance Summit
DESCRIPTION:The 10th Antigen-Specific Immune Tolerance Summit returns to Boston this March\, bringing together the scientific\, clinical\, and industry leaders advancing antigen-specific therapies for autoimmune disease. \nAs leading programs generate pivotal clinical data and progress toward key development milestones\, the field is entering a new phase of clinical and commercial maturity. The meeting is designed to address the challenges most critical to developers of antigen-specific therapies\, including defining durable tolerance\, identifying meaningful biomarkers\, improving translational success\, optimizing antigen selection\, and generating the evidence needed to support regulatory and investment decisions. \nThe speaker faculty includes leaders from Diamyd Medical\, COUR Pharmaceuticals\, Parvus Therapeutics\, Eli Lilly & Co.\, Pfizer\, Bonsai Biotherapeutics\, and Boehringer Ingelheim\, alongside experts from academia\, investment\, and nonprofit organizations. Attendees will gain practical insights from both preclinical and clinical experience across autoimmune indications\, with discussions spanning development strategy\, biomarker selection\, trial design\, and commercialization pathways. \nView the full program to see what insights you can gain: https://ter.li/5tilo5ny \nKey sessions will explore clinically relevant biomarkers of tolerance\, the predictive value of preclinical models\, monitoring technologies for assessing therapeutic efficacy\, and the growing interest in combination approaches to achieve durable immune tolerance. Dedicated discussions on partnership and investment will also examine the evidence pharmaceutical companies and investors seek when evaluating emerging immune tolerance platforms. \nFor the first time\, the summit will take place as part of World Immune Tolerance Week\, alongside the 9th Treg-Directed Therapies Summit and the 2nd Immune Resetting: B-Cell Mediated & Beyond Summit. This co-located format provides broader visibility into complementary therapeutic approaches and opportunities to connect with decision-makers from across immunology\, autoimmune disease\, and precision medicine. \nSee what the previous attendees have to say: \n“It is truly the annual meeting in the ASIT field\, bringing together a community dedicated to sharing knowledge\, exchanging insights\, and celebrating the advances shaping the field”. \nChief Executive Officer\, Bonsai Biotherapeutics \n“As antigen-specific tolerance rapidly transitions from concept to clinic\, this summit stands out as a unique forum bridging immunology\, bioengineering\, and therapeutic development”. \nInstructor\, Division of Immunology & Rheumatology\, Stanford University \nCo-Founder & Scientific Advisor\, EBVio
URL:http://www.pharmajournalist.com/event/10th-antigen-specific-immune-tolerance-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR